The present invention relates to oral composition and the method of preparation and use of such composition for inhibiting, reducing, and/or disrupting oral biofilm. The composition comprises a stabilizing matrix, a cationic biocide, and a peroxide source.

A modified bentonite of biostatic and biocidal properties, the modified bentonite comprising intercalated bentonite grains, wherein each of the intercalated bentonite grains is intercalated with at least two different metal ions selected from the group consisting of silver ions (Ag.sup.+) and dipositive metal ions (Me.sup.2+).

The present invention relates to a A bactericidal or bacteriostatic composition comprising an acetal or a hexitan ether preferentially of a long-chain alkyl sorbitan, arlitan or mannitan, its use in the treatment or prevention of Gram-positive bacterial infections, its use as a hygiene or dermatological product for external use and a method for disinfecting surfaces.

A stable and safe skin antiseptic solution comprises chlorhexidine, pharmaceutically acceptable salts of chlorhexidine (e.g. chlorhexidine digluconate), or a mixture thereof, dimethyl lauramide/myristamide, and water. Said solution is essentially free of coconut oil diethanolamine concentrate (“cocamide DEA”), a known carcinogen. The active antiseptic ingredient, chlorhexidine (or its salts), is a di(4-chlorophenyldiguanido) compound. The functions of dimethyl lauramide/myristamide in said solution include, but not limited to, an aesthetics enhancer, a foam stabilizer, a solubilizer, and a fragrance. Said solution is specifically formulated to be safe with a reduced risk of carcinogenicity, and be capable of producing a stable and long lasting foam. The active antiseptic agent is evenly distributed in said solution and in said foam, respectively.

The present invention relates to an anti-influenza virus composition containing a Poncirus trifoliata extract as an active ingredient. The composition of the present invention inhibits influenza virus replication and infection, thereby exhibiting excellent effects in the prevention and treatment of influenza virus infection. The present invention provides a composition for preventing, treating, or alleviating diseases caused by influenza virus.

The present invention relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof. Furthermore the present invention also relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof and chlorhexidine or pharmaceutically acceptable salts thereof. More particularly, the present invention relates to stable oral topical aqueous pharmaceutical compositions of these combinations having desired levels of solubility, enhanced taste and absorption from mucosal surface, wherein the pH of the solution is between 6 and 7.

Described are stable topical formulations useful in the treatment of viral wart infection, demodex infection and bacterial infection of the skin, and genitalia and the method of treating viral wart infection, demodex infection and bacterial infection of the skin, and genitalia with said compositions.

The present application describes an antimicrobial composition comprising lauric arginate ethyl ester (LAE) and hydrogen peroxide and the use of this composition for disinfecting and sanitizing different types of surfaces such as food products, human skin or mucosa and hard surfaces as well as a method of stabilizing the composition by including a sequestering agent (citrate salt and/or phosphate salt).

The disclosure relates to thiosulfur containing compositions, in particular propyl-propane thiosulfonate (PTSO) and propyl-propane-thiosulfinate (PTS). Such compositions are useful for treating infection and reducing or degrading biofilms both in vivo and in vitro. In particular, such compositions are useful in the treatment of biofilm-related disorders, including but not limited to mastitis, digital dermatitis, and chronic wound infections.

The disclosure relates to thiosulfur containing compositions, in particular propyl-propane thiosulfonate (PTSO) and propyl-propane-thiosulfinate (PTS). Such compositions are useful for treating infection and reducing or degrading biofilms both in vivo and in vitro. In particular, such compositions are useful in the treatment of biofilm-related disorders, including but not limited to mastitis, digital dermatitis, and chronic wound infections.